Kazia Therapeutics Ltd ADR
KZIA
NASDAQ·Healthcare·Biotechnology·Mkt cap $19.9M
$12.31
▲ +1.23%
P/E
—
Mkt Cap
$19.9M
52-Wk Range
$4.86–$17.40
52-Week Range
$4.86 - $17.40
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 52.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- High volatility (beta 2.2). Larger-than-normal price swings expected.
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+8.0% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying KZIA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
SEP 4, 2026
Reported EPS of -$0.58 vs -$0.61 consensus (+4.3% surprise). Revenue of $166.1K vs $488.9K expected (-66.0%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+4.3%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: BTIG · Sep 1, 2026
vs Industry
How KZIA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.